ALK-Abello Allergy Vaccine Shows Positive Results

Patients allergic to dust mites halved their consumption of inhaled steroids by using ALK-Abello’s investigational vaccine tablets in a Phase II/III study.

The study enrolled 604 adolescent and adult patients age 14 and older. Taking place at 80 sites in eight European countries, the study showed the vaccine was well tolerated and had a good safety profile, ALK said.

Subjects given the highest dose had a 50 percent median reduction in their use of inhaled steroids compared with the amount they used before treatment. The effect was statistically significant compared with placebo.

The company’s U.S. partner, Schering-Plough, has licensed the North American rights to the vaccine.